an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma (rGB) (NCT 05324501) at the Preston Robert Tisch Brain Tumor Center at Duke University, USA.
Patients with primary brain tumor (PBT) commonly suffer from insomnia and other sleep disturbance. Managing sleep-related symptoms is an often reported struggle in this population.
perimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice. This is according to a new research study published in the journal Cell, reported by investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Sourasky Medical Center says AI platform under trial delivered accurate genomic analysis data for 2 brain cancer patients, cutting down days of waiting to start treatment
xpansion of preoperative edema (PE) is an independent poor prognostic factor in high-grade gliomas. Evaluation of PE provides important information that can be readily obtained from magnetic resonance imaging (MRI), but there are few reports on factors associated with PE. The goal of this study was to identify factors contributing to PE in Grade 3 (G3) and Grade 4 (G4) gliomas.
An international research group has investigated the mechanisms of cell migration and the impact of tissue rigidity on cell positioning and steering. The research sheds light on e.g. cancer cell migration and opens new possibilities for stopping and directing it.
Today, the National Comprehensive Cancer Network® (NCCN®) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Central Nervous System (CNS) Cancers. This is now the fifth current NCCN Guidelines® to focus on childrens’ cancers, following recent publications of evidence-based, expert consensus guidelines for Pediatric Acute Lymphoblastic Leukemia, Pediatric Aggressive Mature B-Cell Lymphomas, Pediatric Hodgkin Lymphoma, and Wilms Tumors. Though rare, pediatric brain tumors are the second-most-common type of pediatric malignancy after leukemia and are the leading cause of cancer-related death in children.
Brad Pitt arrives at the 2020 Oscars at the Dolby Theatre in Los Angeles. Photo: The Associated Press
By News@TheU
07-08-2022
Prosopagnosia, an ailment that made headlines this week after actor Brad Pitt announced that he is suffering from the disorder, is an uncommon brain malady that causes the inability to recognize faces.
Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists have long known about the variety of cells within a brain tumor, the ways these tumors grow has relied on the understanding that the cells are static, unmoving and relatively fixed.
The classification of brain tumors – and thus the choice of optimal treatment options – can become more accurate and precise through the use of artificial intelligence in combination with physiological imaging. This is the result of an extensive study conducted by the Karl Landsteiner University for Health Sciences (KL Krems). Multiclass machine learning methods were used to analyze and classify brain tumors using physiological data from magnetic resonance imaging.
The FDA has granted an orphan drug designation (ODD) to paxalisib (GDC-0084), for the treatment of patients with atypical rhabdoid or teratoid tumors (AT/RT) in rare and aggressive childhood brain cancer, according to Kazia Therapeutics Limited.1
In 2000, Yu and colleagues in the Yu Laboratory began testing a new way to treat glioblastoma tumors, which are difficult to remove surgically and resistant to chemotherapy and radiation treatment. They started by removing immune cells called dendritic cells from each patient’s blood. “They’re the cells that alert the rest of the immune system when something is wrong,” Yu said.
Researchers at the University of São Paulo, Brazil, injected Zika virus into live mice and cerebral organoids, brain-like organs created in vitro from stem cells. This prevented further growth of the tumors and reduced them in size. A series of injections destroyed the cancer without causing neurological damage or injuring other organs.
Special news came out of the Fralin Biomedical Research Institute at Virginia Tech Thursday. Researchers at the school have successfully identified a potential future treatment for patients with a form of brain cancer called glioblastoma. Patients usually only live for 15 months following their diagnosis. Researchers said in many patients, that’s because the cancer resists chemotherapy treatments. But they have identified two proteins, when paired with an existing chemotherapy treatment, that overcome that resistance.
A new approach to brain tumor treatment using photodynamic therapy (PDT) with nanotechnology has been explored in a review published in the journal Biomedicines. Unlike radiotherapy and surgical resection, PDT can treat micro-invasive areas and protect critical brain tissue with a high probability of success.
Benefits Of Cannabis: CBD Shrinks Size Of Brain Tumor Glioblastoma In Experimental Model
Cannabidiol (CBD) is one of the most abundant compounds in cannabis. It is being touted as a treatment for numerous condition. Researchers find positive results in brain tumour treatment as well.
In the central nervous system, microglial cells play critical roles in development, aging, brain homeostasis, and pathology. Recent studies have shown variation in the gene-expression profile and phenotype of microglia across brain regions and between different age and disease states. But the molecular mechanisms that contribute to these transcriptomic changes in the human brain are not well understood. Now, a new study targets the methylation profile of microglia from human brain.
Researchers at the Medical College of Georgia at Augusta University are providing some hope to those suffering from brain tumors through its new study that revealed that inhaled CBD shrinks the size of glioblastoma tumors in an animal model.
Convolutional neural networks (CNNs) for brain tumor segmentation are generally developed using complete sets of magnetic resonance imaging (MRI) sequences for both training and inference. As such, these algorithms are not trained for realistic, clinical scenarios where parts of the MRI sequences which were used for training, are missing during inference. T
As 5-year relative survival rates differ greatly between cancer patients treated at early or late stages, early detection of tumors is of great importance to cancer therapy. Cathepsin B (CTSB) is considered as a potential biomarker for the early diagnosis of cancers due to its increased expression in the early stage of many cancer types. As a result, the effective and precise monitoring of CTSB activity offers a way out.
Alpheus Medical targets brain cancer with its drug-device combination sonodynamic therapy, offering a potential new treatment for patients who have few options. The company’s device is used in combination with a cancer cell-targeting drug to induce apoptosis in solid tumors.
Inhaled CBD shrinks the size of the highly aggressive, lethal brain tumor glioblastoma in an animal model by reducing the essential support of its microenvironment, researchers report.
Drugs developed to treat AIDS and HIV could offer hope to patients diagnosed with the most common form of primary brain tumour. The breakthrough, co-funded by the charity Brain Tumour Research, is significant because, if further research is conclusive, the anti-retroviral drugs could be prescribed for patients diagnosed with meningioma and acoustic neuroma brain tumours (also known as schwannoma).
A new DNA nanotechnology-based drug delivery system being created by a team led by a Johns Hopkins engineer may improve treatments and survival rates by better targeting the primary tumor. "One of the biggest hurdles to delivering treatments via the bloodstream is crossing the blood brain barrier, which not only protects the brain from toxins in the bloodstream, but can also block out large molecules like therapeutics.
Surgeons at Lenox Hill Hospital are recruiting patients for a first-in-human, single arm, open-label phase 1 clinical trial investigating the safety and feasibility of using belly fat to treat recurrent glioblastoma. A team led by John A. Boockvar, MD, vice chair of neurosurgery and director of the Brain Tumor Center at Lenox Hill and director of the Laboratory for Brain Tumor Biology and Therapy at Feinstein Institutes for Medical Research, is testing the viability of the omental tissue in bypassing the blood-brain barrier and treating the fast-growing, aggressive brain cancer.
Asthma can actually be a protective armor in some cases — against brain tumors. A study, published earlier this month in Nature Communications, explains why people with asthma seem to develop fewer brain tumors.
Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.
Asthma sufferers may actually hold the key to preventing deadly brain tumors, according to a new study. Researchers from Washington University School of Medicine in St. Louis have discovered why people with the breathing condition are less likely to develop these potentially fatal growths.
University of Virginia School of Medicine researchers have developed a noninvasive way to remove faulty brain circuits that could allow doctors to treat debilitating neurological diseases without the need for conventional brain surgery.
A new study by Sonabend, a neurosurgeon, and colleagues at the Northwestern University Feinberg School of Medicine, where he is associate professor of neurosurgery, showed, however, that some patients might benefit from immunotherapy.
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor.
University of Virginia School of Medicine researchers have developed a noninvasive way to remove faulty brain circuits that could allow doctors to treat debilitating neurological diseases without the need for conventional brain surgery.
Oligodendroglioma is a rare type of tumor found in the brain or spinal cord. Imaging tests such as magnetic resonance imaging (MRI) and computed tomography (CT) scans can detect an oligodendroglioma. A biopsy (sampling of tumor tissue) is required for an accurate diagnosis and to establish the grade of the tumor. This article discusses the options for diagnosing oligodendroglioma.
The team identified peptides that are unique to medulloblastoma tumors and then engineered T cells so they could recognize and target those proteins. The T cells eliminated medulloblastoma cells in test tubes.
That's why I was particularly excited to talk with neurosurgery chair Michael Lim, MD, for my latest article for Stanford Medicine magazine. We discussed recent advances in immunotherapy for brain tumors called glioblastomas. I learned that although immunotherapy has proven very effective for many cancer types, brain cancers are particularly challenging.
Doctors and scientists have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.
The technique uses light and nanoparticles to pry open temporarily these barriers — called tight junctions — to allow medication to reach its target.
A team of researchers led by Hong Chen at Washington University in St. Louis has developed a noninvasive diagnostic method that may one day replace the tissue biopsy with a simple blood test.
A recent study demonstrates that magnetic resonance imaging (MRI) and artificial intelligence (AI) can be used to d
tect early signs of tumor cell death in response to a novel virus-based cancer therapy. Researchers used quantitative molecular MRI images to measure multiple tissue properties that are altered with cell-death.
Future investigation of this approach in human brain tumor patients would help to optimize virus-based therapies.
A new therapy that combines copper ions with a drug once heralded as a treatment for alcoholism may help save children from a common but devastating central nervous system cancer known as medulloblastoma.
Treatment with arginine, one of the amino-acid building blocks of proteins, enhanced the effectiveness of radiation therapy in cancer patients with brain metastases, in a proof-of-concept, randomized clinical trial from investigators at Weill Cornell Medicine and Angel H. Roffo Cancer Institute.
The test—which can distinguish between extremely high-risk medulloblastoma cases that need radiation therapy from those that are lower-risk and do not need radiation—could help pave the way for personalized treatment options for children suffering from the disease.
A new study shows that following a Keto diet alters brain and body metabolism in people with brain tumors.
Researchers from University of Fukui, Japan, have used high-density nanofibers that mimic the microenvironment of the brain to capture these tumor cells, opening doors to novel therapeutic solutions for aggressive brain cancer.
Glioblastoma multiformes is a potentially devastating brain tumor. Now, a collaboration between UConn Health and The Jackson Laboratory (JAX) is discovering what makes them so adaptable and dangerous and sometimes able to evade treatments.
Metformin, a drug commonly prescribed against diabetes, holds promise against a rare type of childhood brain tumor in laboratory studies, an international team of researchers led by the University of Michigan Health Rogel Cancer Center report in Science Translational Medicine.
Artificial intelligence (AI) machine learning is helping scientists and researchers find new treatments for diseases and conditions. A new study published in Cancer Discovery shows how AI machine learning can identify a new possible treatment for incurable pediatric brain cancer.
Researchers hope to replicate the successes in pediatric acute lymphoblastic leukemia — among the most common pediatric cancers — by using chimeric antigen receptor T cells to treat brain and CNS tumors. Although this modality has greatly improved outcomes for patients with advanced blood cancers, the challenges of treating solid tumors with CAR-T in such sensitive locations will require novel approaches.
A team of researchers from Weill Cornell Medicine, together with New York Genome Center, Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors.
The findings, along with the methods developed to obtain them, represent a significant advance in cancer research. The researchers believe that their results may ultimately lead to better ways of detecting, monitoring, and treating cancers.
A new study by USC researchers suggests the spread of cancer to particular areas of the brain might not be random, but rather dependent on where the cancer originated in the body -- possibly offering insights into the eventual prevention and treatment of brain tumors.
A team led by researchers has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors. The findings, along with the methods developed to obtain those findings, represent a significant advance in cancer research, and ultimately may lead to better ways of detecting, monitoring and treating cancers.
Sometimes, cancer forms in one part of the body and later spreads to the brain in a condition called brain metastasis. Scientists have always thought this process to be random, meaning cancer cells set up shop wherever they land in the brain, but new research suggests there’s more organization to the deadly chaos.
A novel virus engineered to target malignant gliomas, which are particularly aggressive brain tumors, may prolong survival, according to a recent phase 1 study.
A team of US-based researchers has used an innovative head-mounted device to shrink a brain tumour – potentially paving the way for a powerful new non-invasive therapy for glioblastoma.
A team of US-based researchers has used an innovative head-mounted device to shrink a brain tumour – potentially paving the way for a powerful new non-invasive therapy for glioblastoma.
Ivy Brain Tumor Center and its partner Sonalasense have announced positive initial results in a first-in-human Phase 0/1 clinical trial involving recurrent glioblastoma patients. Sonalasense has developed a sonodynamic therapy (SDT) that pairs low-intensity ultrasound with chemotherapeutic agents known as sonosensitizers. The therapy is noninvasive.
And that's when they stumbled upon a novel clinical trial that combines immunotherapy and minimally invasive brain surgery at University Hospitals Seidman Cancer Center. Led by Dr. Andrew Sloan, this option gave Noonan years to live, instead of the months that other doctors had told her she had. And within six months of starting the trial, Noonan received welcome news.
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG). The study found that ribociclib achieved pharmacologically-relevant concentrations in gadolinium (Gd)-non-enhancing tumor, consistent with the observed tumor pharmacodynamics (PD) effects; while everolimus demonstrated minimal penetration in the (Gd)-non-enhancing compartment of the tumor.
Mayo Clinic researchers alongside the Google Research Brain Team developed a new artificial intelligence algorithm to improve brain stimulation devices to treat movement disorders and epilepsy.
McGill University researchers identify proteins that drive cancer stem cells. Targeting and supressing a particular protein called galectin1 could provide a more effective treatment for glioblastoma, in combination with radiation therapy.
Stereotactic radiosurgery (SRS) is a well-established procedure for the non-invasive treatment of many primary and metastatic brain tumors, as well cranial functional and vascular disorders such as trigeminal neuralgia and arteriovenous malformations. Often considered an alternative to costly and invasive surgical procedures, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet requires no surgical incision, and little to no patient recovery period.
“We are actually treating and have been treating stereotactic brain cancer in Saskatoon since 2016,” Belitski said. “It’s a highly precise, highly conformal treatment, so it does require a lot of planning and treatment delivery. This tool helps increase the efficiency of the planning and treatment delivery, and allows that treatment to be done quicker.”
Dr. Anton Yuryev, Professional Services Director, Elsevier, explores the increasing importance of artificial intelligence (AI) within drug discovery and precision medicine and how it is helping to discover new treatments for children with aggressive brain tumours.
A team of researchers at Texas A&M University, Northwestern University, and ImmunoGenesis has discovered a treatment for glioblastoma that has promising implications for the human version of the aggressive cancer form that grows in the brain.
GammaTile is an implantable radiation therapy consisting of bioresorbable collagen tiles embedded with Cesium-131 sources provided by Isoray, Inc. It is the first medical device cleared for brain tumor treatment in the U.S. in the last ten years. "GammaTile Therapy improves the lives of patients with newly diagnosed malignant and recurrent brain tumors," said Matthew Likens, president and CEO of GT Medical Technologies, Inc.
This XR platform will serve the specialists at the departments of Neurosurgery and Pediatric Neurosurgery, allowing them to plan surgeries and navigate via 3D technology, instead of relying on two-dimensional CT and MRI scans.
Single MRI scan can classify brain tumours using deep learning model
An automated MR image segmentation algorithm can generate 3D models of brain tumors that neurosurgeons can use for augmented reality (AR)-based viewing and surgical planning, according to research published in the Journal of Neurosurgery. These models are then automatically optimized and prepared for neurosurgeons to view in 3D on a computer or AR headset.
A deep-learning model was able to classify brain tumors as one of six common types on a single 3D MRI scan, according to a study published August 11 in Radiology: Artificial Intelligence. The findings could translate to improved workflow and better brain tumor diagnosis, wrote a team led by doctoral student Satrajit Chakrabarty of Washington University School of Medicine in St. Louis, MO.
Early detection of brain tumors is one step closer with breakthroughs made by cancer diagnostics firm and Dxcover, a spin-out firm at the University of Strathclyde. The company has an innovative inspection technology, Dxcover Liquid Biopsy. cancer Growth in smaller quantities and lower stages.
Daiichi Sankyo Company, Limited announced that it has received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for DELYTACT® (teserpaturev/G47∆), an oncolytic virus("OV"), for the treatment of patients with GBM, becoming the world's first OV therapy approved for brain tumors.
A new brain tumor treatment appeared to shrink a man’s aggressive glioblastoma tumor by nearly a third — and all he had to do was wear a noninvasive helmet at home. Treatment usually starts with risky surgery to remove the bulk of the brain tumor, after which a patient might undergo chemo or radiation therapy. “Our results…open a new world of non-invasive and nontoxic therapy for brain cancer.”
In ongoing efforts to catch all forms of cancer in its early stages, researchers are making important inroads when it comes to urine and blood tests that detect the disease. Scientists in the UK have identified a promising new possibility in this area, demonstrating a first-of-a-kind test that can detect tiny DNA mutations shed by dying tumor cells in bodily fluids.
Medical researchers from the University of Cambridge have developed two new tests able to detect the presence of glioma, which is a type of brain tumor. The tumor can be detected using the newly developed tests in the urine or blood plasma of the patient. Researchers note that detecting glioma using urine is the first test of its kind in the world.
We’ve seen helmets and AI that can spot brain tumors, but a new hard hat can actually treat them, too. As part of the latest neurological breakthrough, researchers used a helmet that generates a magnetic field to shrink a deadly tumor by a third.
Staff at University of Arkansas for Medical Sciences (UAMS) have performed the state’s first application of GammaTile Therapy. Radiation oncologist Richard Crownover, M.D., Ph.D., and neurosurgeon Analiz Rodriguez, M.D., Ph.D., and their care team successfully embedded the therapy into a patient and veteran from Horseshoe Bend. GammaTile Therapy, marketed by GT Medical Technologies and also known as surgically targeted radiation therapy (STaRT), is designed to delay brain tumor recurrence. It consists of a 3D-collagen tile embedded with a cesium radiation source.
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its plans for a new 75,000-square-foot headquarters, with construction beginning in August. The five-story building will be the largest translational research center dedicated to brain tumor drug development in the world.
A new study indicated that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2 (NF2), a hereditary condition associated with vestibular schwannomas, or noncancerous tumours along the nerves in the brain that are involved with hearing and balance.
Scientists at the University of New Mexico’s Cancer Center are studying brain cancer and why tumors often come back. One local firefighter who knows this all too well, says this kind of research will make a world of difference for patients like him.
In a new study, scientists at Uppsala University have discovered structures similar to lymph nodes where T lymphocytes could be activated. These lymph node-like structures were found near the tumor in brain cancer patients. In addition, it was also discovered that immunotherapy enhanced the formation of these structures in a mouse model.
Researchers at Uppsala University have discovered lymph node-like structures close to the tumor in brain cancer patients, where immune cells can be activated to attack the tumor. They also found that immunotherapy enhanced the formation of these structures in a mouse model. This discovery suggests new opportunities to regulate the anti-tumor response of the immune system.
Scientists have now discovered a new resting phase for neuroepithelial cells – the stem cells of the central nervous system – which appears to put them in a kind of dormancy. If we can work out how to apply this to cancer cells too, we could get to the stage of being able to put brain tumors to ‘sleep’.
Discovery that levels of a specific protein detected through urine can track a tumor’s size and responsiveness to treatment in children with diffuse intrinsic pontine gliomas (DIPG) helps pave the wave for more innovative and less invasive treatment options for this aggressive brain tumor.
Research led by USC investigators has shined new light on how medulloblastoma travels to other sites within the central nervous system. The study, which appeared in the journal Cell Reports, showed that an enzyme called GABA transaminase, abbreviated as ABAT, aids metastases in surviving the hostile environment around the brain and spinal cord and in resisting treatment.
For the first time, a team at the University of Virginia has treated a glioblastoma patient using focused ultrasound. According to a release, the patient is part of a multicenter clinical trial that is evaluating the safety of using focused ultrasound to enhance the delivery of chemotherapy in patients with glioblastoma multiforme.
Branded as LUMINOS-101, the therapy combines a viral immunotherapy based on the polio vaccine with an immunotherapy drug shown to be effective in other types of cancers. Evidence indicates these agents – oncolytic polio/rhinovirus recombinant (known as PVSRIPO) and pembrolizumab (marketed under the name Keytruda) – can work together to catalyze the immune system’s cancer-fighting response.
A recent study by Nagoya University researchers revealed that microRNAs in urine could be a promising biomarker to diagnose brain tumors. Their findings, published in the journal ACS Applied Materials & Interfaces, have indicated that regular urine tests could help early detection and treatment of brain tumors, possibly leading to improved patient survival.
A new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease. Two of the first 20 patients treated for a highly aggressive type of brain cancer called glioblastoma responded to lisavanbulin, a type of targeted cancer drug.
Newly announced results from a preliminary clinical trial testing a novel kind of brain cancer drug have revealed incredibly promising responses in a particular subset of patients. A larger Phase 2 trial is now underway targeting patients with a specific biomarker.
Treatment with AV-GBM-1, a personalized cancer vaccine, was associated with a significant survival outcome improvement compared to standard-of-care therapies in patients with newly diagnosed glioblastoma, according to the vaccine’s manufacturer, AIVITA Biomedical Inc.
With the rise of VR and advancing surgical techniques, neurosurgical teams are developing an increased understanding of patients’ anatomo-functional connectivity. Consequently, more specific cognitive tasks are being required for the mapping and preservation of deeper layers of cognition.
Incorporating functional MRI (fMRI) into brain tumor resection planning can help reduce the possibility of negative outcomes patients might experience after surgery. In a study published in the June 1 Radiology, investigators from Johns Hopkins Hospital showed that using fMRI is an effective way to safeguard brain cancer patients health.
Michigan Medicine's neurosurgery team increased accuracy rate from 68% to 96% by developing a computer vision model to help improve pathologist decision support.
Neuro-oncologist Dr. Santosh Kesari talks about the difficulties of treating brain cancer and the promise that mRNA vaccines hold
Two experimental drug approaches may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer, researchers report.
Researchers have discovered the mechanism brain tumors use to "paralyze" the immune system and simultaneously learned how to reactivate it to target the brain tumor, according to a new study published in the journal Nature. And as a bonus: this study confirms that therapeutic vaccines (also called immunotherapies) have a greater effect on brain tumors if active substances are simultaneously used to revitalize the immune system.
CyberKnife is a treatment option for those with brain tumors who choose not to undergo surgery, or who are not good surgical candidates due to age, health, or other reasons. With CyberKnife, patients can keep their current neurosurgeon, who they know and trust, and have them involved in their case.
A non-invasive Brain Cancer Treatment has been announced by Ivy Brain Tumor Center, SonALAsense and Insightec: The First Patient Dosed in First-in-Human Clinical Trial of Non-invasive Sonodynamic Therapy for the Treatment of Brain Cancer. The study combines metabolic targeting of glioblastoma with inert drug activated using MRI-guided focused ultrasound.
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
According to Dr. Richard Curry, neuro-oncologist and director of neurology for the TriHealth Neuroscience Institute, progress in discovering new and better treatments for brain cancer has been slow compared to improvements in more common types of cancer, such as breast or lung cancer. On the positive side, he has seen advances in surgeons’ ability to more precisely target and surgically remove a brain tumor. Curry also applauds the ability to use radiation therapy more precisely to target cancerous tissue in the brain and spare healthy tissue.
Research teams in Austria and Sweden have succeeded in administering chemotherapeutic agents in a targeted manner with the aid of an ion pump and this is the first time an ion pump has been tested as a possible method for treating malignant brain tumours. They have been delivering gemcitabine, an extremely effective chemotherapeutic agent, directly to the tumour in the brain with the help of an implanted ion pump, thereby bypassing the blood-brain barrier too.
Scientists have published a new study detailing the use of tumor-promoting immune cells to attack an aggressive, often fatal form of brain cancer. The work involves ‘reprogramming’ these cells so that they switch from protecting cancerous brain tumors to attacking them.
The brain cancer research field has expanded and advanced in recent years, as scientists and physicians increase their knowledge of the disease. CURE® spoke with David Arons, CEO of the National Brain Tumor Society, about the latest changes patients should be aware of, and what they can look forward to in the future. “Over the last few years, there’s been some important advancements, particularly in understanding how brain tumors evolve, and then identifying potential vulnerabilities in brain tumors with opportunities to attack them,” Arons said.
John’s amazing life story has been told in many local and international news/magazine articles. A documentary about his life, Escape From Room 18, is often aired on Yes Docu, especially during Holocaust Memorial Day. The earlier Jerusalem Post articles also appeared in the paper’s international edition and have been read by high school students in Europe, the US and Canada.
The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for PU-AD (icapamespib), an epichaperome inhibitor for recurrent malignant glioma developed by privately held biopharmaceutical company Samus Therapeutics. Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
Researchers at Massachusetts General Hospital (MGH), the Dana-Farber Cancer Institute and other Boston-area research centers are turning the tables on glioblastomas, the most devastating and aggressive form of brain cancer, by transforming a type of cell that normally protects tumors and inhibits effective drug therapy into a stone-cold glioblastoma killer.
A team studying malignant brain tumors has developed a new technique for predicting how individual patients will respond to chemoradiation, a major step forward in efforts to personalize cancer treatment. Researchers at The University of Texas at Austin have merged various quantitative imaging measurements with computational simulations to create an accurate model for calculating the progression of high-grade glioma.
These sensors are recording where these electrical signals are rising from your brain. The goal is to create a customized brain map that helps the surgical team remove as much of a brain tumor as possible while minimizing possible damage caused by the physical act of removing the tumor.
In experiments with cancer cells, research teams in Austria and Sweden have now succeeded in administering chemotherapeutic agents in a targeted manner with the aid of an ion pump. This should also lead to less severe side effects from the therapy.
For decades, a deadly type of childhood cancer has eluded science’s best tools. Now doctors have made progress with an unusual treatment: Dripping millions of copies of a virus directly into kids’ brains to infect their tumors and spur an immune system attack.
A team of researchers at Fralin Biomedical Research Institute at VTC and City of Hope, a comprehensive care center, believes the complex way fluid flows through glioblastoma tumors holds the key to the therapy's success.
SynNotch-CAR T cell therapy is able to precisely target glioblastoma brain tumors.
For decades, a deadly type of childhood cancer has eluded science's best tools. Now doctors have made progress with an unusual treatment: dripping millions of copies of a virus directly into children's brains to infect their tumors and spur an immune system attack.
As a non-invasive treatment for select brain tumors and brain metastases, SRS is a well-studied and proven procedure that often provides equivalent or superior outcomes to surgery. Unlike surgery however, radiosurgery requires no incision and is painless.
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Cell Reports, offers an exciting new therapeutic approach for the treatment of DIPG by using a new anti-cancer drug. The new drug, CBL0137, is an anti-cancer compound developed from the antimalarial drug quinacrine.
Scientists at Sweden's Linköping University have developed a new tool to tackle these risky remnants of malignant tumors, demonstrating how an ion pump can take highly effective chemotherapy drugs directly to the source of the problem.
Scientists from Queen Mary University of London, funded by the charity Brain Tumour Research, have found a new way to starve cancerous brain tumour cells of energy in order to prevent further growth. The pre-clinical research in human tissue samples, human cell lines and mice could lead to changes in the way that some children with medulloblastoma are treated in the future.
Glioblastoma in rodents, and in human cells in a lab model, blocked by compound that researchers see as ‘paving the way for a new therapy’ for deadliest brain cancer Glioblastoma in rodents, and in human cells in a lab model, blocked by compound that researchers see as ‘paving the way for a new therapy’ for deadliest brain cancer.
A modified herpes virus, alone and in combination with radiation, has been shown to be well tolerated with early signs of clinical effectiveness in pediatric patients with high-grade brain tumors, or gliomas, according to findings from researchers at the University of Alabama at Birmingham and Children’s of Alabama.
Researchers at the University of Alabama at Birmingham have identified a potential pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer.
Now, new medical technology is offering what medical experts call a game changer. GammaTile therapy, a type of surgically targeted radiation therapy, is helping cancer patients to recover from brain tumor resection surgeries. GammaTile is a collagen tile that has a radiation source embedded in it. After a surgeon resects the tumor, the tile is placed inside the tumor bed, where it stays inside a person’s brain. It delivers radiation therapy from the moment it is inserted.
In a paper published in Scientific Reports last week, Yale researchers presented their development of a new sodium magnetic resonance spectroscopic imaging, or MRSI, method that will help detect gliomas, a type of brain tumor, in a non-invasive way.
The research, performed in animal models and human and mouse cells in culture, was published in the Journal of Clinical Investigation. The findings indicate that an adhesive cell surface protein known as N-cadherin — or N-cad — may be key in overcoming glioblastoma’s resistance to radiation therapy.
The Zika virus can activate immune cells to destroy an aggressive brain cancer in mice, giving a powerful boost to an immunotherapy drug and sparking long-lasting immunological memory that can ward off tumor recurrence for at least 18 months, according to a study posted on the website of Washington University School of Medicine in St. Louis on Wednesday. To better understand how Zika virus works against brain cancer, researchers at the university transplanted brain cancer cells into the brains of mice. One week later, they injected Zika virus into the mice's quickly growing tumors, or sterile saltwater for comparison.
Researchers and doctors from several centres across Germany, including the German Cancer Research Center, and the National Center for Tumor Diseases (NCT), carried out the first clinical trial to test a new vaccine against malignant brain tumours, according to a study published in the journal Nature (1). The results were very promising. Not only the vaccine was safe for all patients, but it also started the desired immune response in the cancerous tissue.
Physicians and cancer researchers in Heidelberg and Mannheim have for the first time carried out a clinical trial to test a cancer vaccine candidate that targets a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene. Results from the first-in-human Phase I study in glioma patients showed that repeated injections of the peptide vaccine were safe, and triggered the anticipated immune response in their tumor tissue.
There's a high probability that radio-frequency radiation from cellphones causes certain rare but often malignant brain tumors in humans, according to a former director of the National Center for Environmental Health at the Centers for Disease Control and Prevention. Dr. Christopher Portier submitted his findings as part of a lawsuit by patients and families against multiple cellphone manufacturers and carriers.
It has been reported that a new glioma-targeted nano-therapeutic that will only address tumor cells offering increased effectiveness and reduced side effects.
Brainstem glioma is often diagnosed in children and young adults and has a low survival rate. A multidisciplinary team at Washington University in St. Louis developed a technique that delivered a therapeutic agent to the gliomas using focused ultrasound with very promising results.
University Hospitals is using the Stealth Autoguide cranial robotic guidance platform, developed by Medtronic, to perform biopsies on brain cancer patients and other neurological procedures.
A simple blood test could reduce, or in some cases replace, the need for intrusive surgery when determining the best course of treatment for patients with a specific type of brain tumor, a new study finds. The researchers have discovered a biomarker, known as the protein Fibulin-2 (FBLN2), which helps to distinguish whether meningioma — the most common form of adult primary brain tumor — is a grade I or grade II.. Read more at: https://www.newsgram.com/study-simple-blood-test-can-treat-specific-type-of-brain-tumor/
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
A new study in Barcelona, Spain used personalized transcriptome sequencing to show that immune cells within the cerebrospinal fluid, particularly CD8 T-cells, faithfully model the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
Shear wave elastography can outperform MRI in pinpointing whether any malignant tissue has been left behind after brain surgery. In a new study published in Frontiers in Oncology, a multi-institutional team discovered shear wave elastography was a much more sensitive technique.
A type of ultrasound scan can detect cancer tissue left behind after a brain tumor is removed more sensitively than surgeons, and could improve the outcome from operations, a new study suggests.
The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries and breakthroughs in oncology, especially those targeting glioblastoma.
“They drill a small hole in the bone or the skull,” Desjardins says. “It’s just above the tumor. Then, they put a small needle in.” It’s similar to a brain biopsy, but instead of taking a sample out, they put something in the brain. In this case, it was a bacterial toxin that attached to the receptors of the tumor cells.
New analysis of 3D images and quantitative data "will help to appreciate from within how the tumor is built in its full dimensionality, and to identify where different cell types are located", explains George Paul Cribaro, first author of the study. "It provides more complete information than the usual 2D analyses performed for neuropathological diagnosis".
A research team from both Scottish and UK institutions using infrared spectroscopy at Diamond Light Source reports a major advance in brain tumor diagnosis made by. This will enable non-invasive diagnoses of primary brain tumors (gliomas) and accelerate results as they will be available in real-time from a read out showing the kinds of mutations present in the gliomas of their patient.
Scientists from Korea and China have developed a multi-functional platform using gold nanostructures that allows growth of 3D spheroid cancer cells and their real-time monitoring under drug treatment in a non-invasive and repeatable fashion, crowning a novel approach to creating a realistic brain tumor model along with a rapid and precise method for anti-cancer drug screening.
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments.
Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests.
A new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments.
Researchers found that up to 20% of glioblastomas have overactive cellular power plants (mitochondria) and that their cells are relying on them for all their energy. This type of glioblastoma is associated with a slightly longer survival time, and its dependence on fuel generated by mitochondria may make it especially vulnerable to drugs that inhibit the structures.
A promising non-invasive treatment to effectively and safely destroy deadly brain tumors is being tested on human patients for the first time ever at the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix. This new treatment has shown to be incredibly effective in treating aggressive brain tumors in animals, said Dr. Shwetal Mehta, a molecular neuro-oncologist and the chief operating officer and deputy director of the center.
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they’ve grown back, enabling up to 20% of patients to live well beyond predicted survival times.
Mitochondria are responsible for creating the energy that fuels all cells. Though they are usually less efficient at producing energy in cancer, tumor cells in this newly identified type of glioblastoma rely on the extra energy provided by overactive mitochondria to survive.
This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.
“Our research found that the CD200 protein was acting as a protective shield inside a person’s brain tumor, effectively preventing the immune system or immune-directed therapy from attacking the tumor,” said Dr. Olin. “The CD200 checkpoint inhibitor that we developed, along with a proven vaccine, has shown amazing results in our tests and has the potential to have fewer adverse effects for patients.”
“These patients appear to have a much more favorable prognosis and survive for years, if not decades. So, we decided to further investigate whether IDH mutations can predict which patients with low-grade glioma serve to benefit from the addition of chemotherapy to radiation vs. radiation alone.”
A powerful tool in The University of Kansas Health System’s surgical arsenal is the intraoperative MRI. We have an MRI scanner within the operating room, adjacent to the surgical table. Neurosurgeons begin the resection and remove as much of the tumor as we safely can. We then slide the patient on the surgical table directly into the MRI scanner to capture real-time images that may show us more tumor cells that can be removed during the same surgery.
Brain and spine surgeries can come down to mere millimeters in terms of being a success or a failure. At Virginia Brain and Spine Center (VBSC) in Winchester, which partners and works with Valley Health System, new technology is being used so neurosurgeons can perform procedures more efficiently and safely utilizing the Airo Mobile Intraoperative CT and the Curve Image Guided Surgery platform with neuronavigation technology.
Roswell Park Comprehensive Cancer Center has been working on multiple cancer research projects. One of these advancements is a drug called SurVaxM that was designed to treat a form of rare cancer called glioblastoma, will be used in a large clinical trial this year.
It was refreshing to hear about Gleolan, 5-aminolevulinic acid hydrochloride (5-ALA) powder for oral solution for marketing in Canada. It recently received a Notice of Compliance from Health Canada and is indicated in patients with glioma World Health Organization (WHO) Grades III or IV (suspected on preoperative imaging), as an adjunct for the visualization of malignant tissue during surgery.
Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now.
You must first understand how something works normally before you can figure out why it's broken. A researcher has now identified six mini gene co-expression networks for a normally functioning brain. That will allow researchers to test each of the gene teams to see if gene pairs are changing in brain tumors or people with intellectual disabilities.
Researchers at the Luxemburg Institute of Health Genes have identified the genes responsible for the extreme invasiveness of glioblastomas and the molecular regulator that switches them on.
The research team leveraged RNA interference -- a technique commonly used to uncover the function of a gene and its contribution to observed cellular characteristics -- to progressively silence and deactivate the entire set of genes of highly invasive patient-derived GBM cells and observe the consequences on the cell's ability to invade healthy tissues.
A Duke University spinout has developed an immune-boosting technology using variations of the polio vaccine that does more than wipe out a targeted solid tumor. “It clears the body of others as well, not just where it’s injected,” said Matt Stober, president and CEO of RTP-based Istari Oncology.
A new approach to cancer immunotherapy has the potential to be a universal treatment for solid tumors, according to researchers at Purdue University. Two Purdue scientists worked together to develop and test the new treatment that works not by attacking the cancer cells themselves, but by focusing on immune system cells that, ironically, feed the tumor and block other immune system cells from destroying it.
A study came out by Penn State College of Medicine suggests that a specific type of white blood cell can cause brain cancer tissues to die. This is good news. And the bad news is that a large number of these tissue deaths correspond to poor survival in patients with aggressive glioblastomas.
A study recently published in the journal Cancer Cell by VCU Massey Cancer Center scientist Suyun Huang, M.D., Ph.D., offers hope for the development of future therapies by showing how a poorly understood gene known as YTHDF3 plays a significant role in the process.
A study shows that different biological and treatment groups within the disease relapse at different times and with different patterns of spread throughout the body. Medulloblastoma is the most common malignant brain tumor in children and relapse following initial treatment has a grave prognosis, according to the authors.
Members of the Children's Brain Tumor Tissue Consortium and the Clinical Proteomic Tumor Analysis Consortium used proteogenomics to search for biological, biomarker, and therapeutic clues across several pediatric brain cancer types, uncovering tumors with possible treatment targets that clustered together proteomically across distinct histological tumor types.
Dr. Mark Hornyak, a Neurosurgeon with Hartford HealthCare’s Backus Hospital, explains more about the procedure.
Researchers at Newcastle University in the U.K. say that experts can identify the time, nature, and outcome of medulloblastoma relapse from the biology of the disease at diagnosis and the initial therapy received.
The researcher team found that the C11orf95 fragment primarily determines to which DNA segments the fusion protein binds. The RELA fragment then stabilizes the binding dynamic and drives the expression of ependymoma-associated genes.
To improve these odds and better match patients with the most appropriate drug protocol, researchers have developed a personalized drug screen that can be used to find the best drug candidate for a patient’s medulloblastoma type.
A new treatment approach for a deadly childhood brain tumor is undergoing trials in Seattle.
Breakthrough assay a ‘tenfold improvement over any prior assay for TERT mutations in the blood for brain tumors,’ MGH says in an affirmation of a diagnostic technology clinical labs might soon use
A new three-dimensional imaging technique has been developed that greatly improves the visibility of brain tumors in magnetic resonance imaging (MRI) scans. The technique, invented by a scientist at Northwestern University Feinberg School of Medicine, will potentially enable earlier diagnosis of tumors when they are smaller and more treatable.
A new three-dimensional imaging technique developed by researchers at Northwestern University Feinberg School of Medicine significantly improves the visibility of brain tumors in magnetic resonance imaging (MRI) scans, potentially enabling earlier diagnosis of tumors.
A study finds a new method of delivering radiation in a fraction of the time traditional therapies take can remove the debilitating after effects of killing tumors.
Scientists have discovered a way to stop the growth of glioblastoma, the deadliest form of brain cancer. The finding provides a new tactic in the war against cancer that involves reprogramming the immune system to do what it does best - fight the tumor instead of fueling it.
Adenocarcinoma in the brain is most often a cancer that has started in the lungs or the colon and spread. It is an aggressive, relentless disease. Now, a new form of treatment is providing increased quality of life for brain tumor patients.
A team of researchers at Massachusetts General Hospital have developed an enhanced form of liquid biopsy that that accurately detect and monitor mutations that promote the development of gliomas, the most common type of adult brain tumor.
An enhanced liquid biopsy test developed by researchers at Massachusetts General Hospital (MGH) has shown improved sensitivity for detecting specific biomarkers in gliomas that shows significant promising in both detecting and monitoring treatments for this deadly form of cancer.
It’s being called a major breakthrough in the fight against cancer. Researchers have developed a blood test that can detect brain tumors early, but that’s not the only thing this new test can do.
Genetic mutations that promote the growth of the most common type of adult brain tumors can be accurately detected and monitored in blood samples using an enhanced form of liquid biopsy developed by researchers at Harvard-affiliated Massachusetts General Hospital (MGH).
Cyberknife M6 is performed in a non-invasive manner with a higher brain surgery recovery time done on outpatient basis. The characteristics of M6 to pinpoint the exact location of the tumor in real time using 3-D imaging techniques during the treatment of brain tumor and ablating the tumor without any cut marks has proven outcomes to overtake the traditional methods of treatment.
A team led by University Hospital Zurich and the University of Zurich tested a protein-based drug that fuses immune-stimulating cytokines with antibodies that specifically target glioblastoma. The drug slowed tumor growth in mouse models of the disease and boosted the ability of immune cells to reach patients' brain tumors in a small, ongoing clinical trial.
This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
A team of scientists from Hokkaido University and Stanford University have revealed a mechanism by which GBM develops radioresistance. Their research, published in the journal Neuro-Oncology Advances, explains how two key molecules, Rab27b and epiregulin, interact to contribute to radioresistance in GBM.
"Advances in combination therapy have created new opportunities in cancer therapeutics, especially with regard to combatting drug resistance and tumor metastasis," said lead author of the study Jawad Fares, MD, Northwestern University.
In an interview with Targeted Oncology, David Roberge, MD, discussed the role of radiation treatment in patients with brain metastases and the clinical trial evaluating treatment approaches for patients with more than 5 brain metastases.
A research team at Korea University College of Medicine has confirmed the anticancer effects of psychoactive drugs in treating malignant brain tumors, suggesting a novel therapeutic approach. A malignant brain tumor is an intractable disease, which leads patients to death after only 12 to 14 months on average, even after receiving treatment. There is a high probability for patients to develop drug tolerance, one of the causes of short survival periods.
A roundup of several recent Michigan Medicine discoveries that are shedding new light on pediatric brain cancers and helping to improve treatment options. In honor of childhood cancer awareness month, here’s a look at a couple of recent research developments from Michigan Medicine.
Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38 for BMBC and rGBM, respectively, and produced partial responses in both cohorts of brain cancer patients.
Doctors at the Oklahoma Medical Research Foundation are celebrating what could become a breakthrough in brain cancer treatment. It's a drug that could become the only answer for those facing the devastating diagnosis. Researcher Dr. Rheal Towner has designed a medicine that fights DIPG, an uncurable form of pediatric brain cancer that effects around 300 children in the U.S. annually.
Using PET with the radiolabeled amino acid F-18 fluoroethyl-tyrosine (F-18-FET) can significantly help determine the efficacy of radiotherapy in certain cancer patients who develop brain metastases, according to a study in the Journal of Nuclear Medicine.
The medical device company NeuroOne Medical Technologies Corporation's new thin-film electrode technology, Evo Cortical, offers a potentially faster and less invasive diagnostic tool for identifying brain abnormalities in patients with epilepsy and brain tumors.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
McMaster University researchers have identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, the most serious form of pediatric brain cancer, making these aggressive forms of the disease more susceptible to therapy.
Brain cancer in children is always a devastating diagnosis, but McMaster University researchers may have found a way to have the most serious types of pediatric brain cancer respond better to therapies.
Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies. The work also found the Wnt pathway, which has historically been considered cancer-promoting, to function as a cancer inhibitor in certain contexts.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
A new and sophisticated twist on the technology that brings us images of a fetus in utero will soon be used by physicians at Miami Neuroscience Institute and Miami Cancer Institute to treat some patients with movement disorders and brain tumors.
